NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
SIM0505 is a novel ADC developed by Simcere Zaiming. It is directed to CDH6, a promising anti-tumor target, using a unique binding epitope with increased tumor binding compared to competing candidates. It also features Simcere Zaiming's proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity while offering high systemic clearance to enlarge the therapeutic window. Preclinical studies have demonstrated robust anti-tumor activity across multiple solid tumor models and a promising safety profile in toxicology models.
SIM0505 is currently in Phase 1 dose escalation studies in China. A global dose expansion study is expected following the dose escalation portion of the study to include multiple tumor types. An Investigational New Drug application has been cleared by the U.S. Food and Drug Administration.
The partnership also includes a license for NextCure to access Simcere Zaiming's proprietary linker and TOPOi payload for a preclinical-stage novel target ADC developed by NextCure. Simcere Zaiming will have Greater China rights to this additional novel target ADC.
'We believe SIM0505 has the potential to be an important new therapy for cancer patients. Partnering with Simcere Zaiming, a leader in antibody-drug conjugates, provides us with an opportunity to advance a class-leading ADC directed to CDH6. Their proprietary payload is a potent cytotoxin with a potentially improved safety and efficacy profile compared to other topoisomerase inhibitors,' said Michael Richman, NextCure's president and CEO. 'We look forward to initiating clinical development of SIM0505 in the United States.'
'We are very pleased to collaborate with NextCure on the global development of SIM0505,' said Renhong Tang, PhD, CEO of Simcere Zaiming. 'SIM0505 is a significantly differentiated CDH6 targeting ADC candidate independently developed by Simcere Zaiming. Our alliance reflects NextCure's recognition of our proprietary ADC platform, and together, we aim to accelerate drug development to benefit more cancer patients worldwide.'
Simcere Zaiming is eligible to receive payments throughout the potential development phases, including upfront payment, development, regulatory and sales milestones up to $745M, as well as tiered royalties up to double digits on net sales outside of the Greater China territory.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, 'Simcere'). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
NextCure's Cautionary Statement Regarding Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'continue,' 'could,' 'should,' 'due,' 'estimate,' 'expect,' 'intend,' 'hope,' 'may,' 'objective,' 'plan,' 'predict,' 'potential,' 'positioned,' 'seek,' 'target,' 'towards,' 'forward,' 'later,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and not having any products approved for commercial sale; NextCure's history of significant losses; NextCure's need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure's ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described under the heading 'Risk Factors' in NextCure's most recent Annual Report on Form 10-K and in NextCure's other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
NextCure Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
[email protected]
Simcere Zaiming Contacts
PR contacts: [email protected]
IR contacts: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch
Key Points Tesla's heavy reliance on Elon Musk adds significant leadership risk. Increasing competition from established automakers and Chinese EV makers is pressuring Tesla's dominance. Investors need to be comfortable with Tesla's high valuation. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been the front runner in the electric vehicle (EV) revolution in the U.S. Its innovation, brand strength, and rapid growth have made it a favorite among investors. Yet, despite its impressive track record, there are two big risks that investors should carefully consider before buying Tesla stock today. 1. The Elon Musk factor Elon Musk's leadership is often cited as Tesla's greatest strength -- and, paradoxically, one of its most significant vulnerabilities. Musk's vision and hands-on approach have driven Tesla's technological breakthroughs and ambitious expansion. However, this heavy reliance on a single individual introduces what investors refer to as "key man risk." If Musk were to step back from daily operations or shift his focus to other projects, Tesla might face challenges in maintaining its momentum. Though Tesla's management team has grown stronger, few executives command the same vision, drive, and public attention as Musk. Recently, Musk's increasing involvement in political activities has raised concerns about potential distractions or reputational risks for Tesla. While the company has remained operationally strong, these developments underscore the uncertainty around its future leadership continuity. While Tesla's success lies not only with Musk but also with his team, which has executed well on his vision -- no one can build a trillion-dollar company alone -- there is still no clear successor (or a viable management team) . The silver lining here is that the Tesla board has become more serious about finding one in recent months, largely due to the CEO's active involvement in politics. For investors, this means that Tesla's fortunes remain closely tied to Musk's presence and decisions -- a factor that adds a layer of risk to the investment. 2. Intensifying competition Tesla might have been an early mover in the EV industry, but its dominance is no longer guaranteed. The industry landscape is rapidly evolving, with legacy automakers and new entrants accelerating their electric ambitions. Companies like Ford and General Motors are aggressively expanding their EV lineups. For instance, Ford plans to introduce a $30,000 midsize truck by 2027. That price is significantly lower than the average for an EV, and Ford is investing $5 billion in its EV production to make it happen. GM, on the other hand, is working hard on next-generation battery technologies to improve range, charging performance, and cost. Meanwhile, Chinese manufacturers such as BYD are growing their international footprints, particularly in Europe, where Tesla experienced a nearly 27% sales declinein July 2025. BYD's battery technology, government support, and competitive pricing make it a formidable challenger. In addition, a host of EV start-ups are innovating in battery tech, autonomous driving, and new business models, further intensifying competition. While Tesla is not sitting still -- it is working on becoming the lowest-cost producer by cutting prices to grow sales volume and achieve economies of scale -- there is no guarantee that it can maintain its market share over time. In short, it's no longer the only player in town. What does this mean for investors? Tesla's story remains compelling: It's a pioneer with a powerful brand, innovative products, and potential optionality with some of its long shot bets (robotaxi, humanoid robots, etc). But the key man risk surrounding Musk and the escalating competitive landscape are real concerns that investors can't ignore. If Tesla continues to innovate more rapidly than its rivals, the company could sustain its growth trajectory. However, any leadership changes or slips in market position could hurt the business and its share price. While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully before buying the stock today. Tesla stock trades at a significant premium valuation to other carmakers. For perspective, Tesla has a price-to-sales (P/S) ratio of 12.9, compared to GM's 0.3. Unless you're comfortable with the risks and the high valuation, buying the stock today may not be a prudent decision. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 13, 2025 Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends BYD Company and General Motors. The Motley Fool has a disclosure policy. Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Chinese port achieves first-of-its-kind transfer that could revolutionize maritime trade: 'Significantly cheaper than land transport'
Chinese port achieves first-of-its-kind transfer that could revolutionize maritime trade: 'Significantly cheaper than land transport' A cargo transfer milestone has been reached at a Chinese port. But the haul wasn't typical products, but rather, air pollution. It's a fascinating achievement that could provide shipping with another revenue stream, astoundingly from ship exhaust, according to the Maritime Executive. Evergreen's 152,300-deadweight-ton Ever Top was retrofitted last year with tech to capture carbon dioxide from exhaust, lassoing nearly 80% of emissions with a nearly 100% purity. The stored fumes can then be sold at a profit for other uses, per ME and Interesting Engineering. The transfer happened on June 19 at the Port of Shanghai thanks to special onboard equipment, including absorption and regeneration modules, compression refrigeration, and storage. Past efforts that used trucks and tanks to offload the CO2 were more complicated. In Shanghai, a barge vessel called De Jin parked alongside Ever Top to complete the move, heralded by Chinese officials as a novel effort, ME reported. "For scaled operations, ship-to-ship transfer offers clear advantages. It is significantly cheaper than land transport and much more efficient," project manager Du Mingsai said in IE's story. The retrofit cost about $10 million. But reports indicated the expense can be more than recouped within two years by selling the stored carbon. ME said that experts estimated ships could make an amazing $8 million a year from selling tailpipe gases. Drax Group, a United Kingdom renewable energy company not involved with the project, listed numerous product uses for captured carbon. Sneakers, furniture, cleaner concrete, and even alternative metal were some of the ones noted. The push to capture carbon comes from efforts within the sector to reduce heat-trapping air pollution that is warming the atmosphere and oceans. The National Oceanic and Atmospheric Administration reported that around 91% of the excess heat produced on Earth is absorbed by the oceans. Coral bleaching, sea level rise, and other problems are linked to the warming waters, per the agency. The European Federation for Transport and Environment reported that the sector produces about 3% of global CO2 fumes, which is expected to grow by half by 2050 if "stringent measures are not taken." New-age sails, kites, and hydrogen fuel are some other options being harnessed to cut the use of dirty energy in maritime travel. But ME reported that the Ever Top retrofit costs less than a new vessel or an alternative fuel conversion. "From onboard storage to mobile transfer and reuse, the milestone gives Shanghai a full-chain ecosystem for maritime carbon capture. It also positions the city as a global model for cutting shipping emissions and sets a new benchmark for the industry's green transition," IE's Neetika Walter wrote. Do you worry about air pollution in your town? All the time Often Only sometimes Never Click your choice to see results and speak your mind. But not all of the headlines coming from the Far East seas are squeaky clean. CBS News reported that China is using so-called "dark" vessels to transfer dirty oil between ships as the country continues to buy the fossil fuel from heavily sanctioned Iran. The ships have disabled their transponders, making them tough to ID. China buys 90% of Iran's oil and calls the transactions legitimate, all according to CBS. Staying informed about key environmental issues can help you judge if efforts happening at home and around the world are legitimately meeting sustainability goals. Sometimes companies and countries tout big projects with little actual progress. Choosing cleaner travel options can also make a difference. Public transportation is a way to curb pollution. Every mile traveled via public means instead of driving cuts about a pound of heat-trapping fumes. The move can also save you serious cash in your transportation budget. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Associated Press
an hour ago
- Associated Press
This Summer's Next Trend? Stationery, Says Yiwugo
YIWU, China, Aug. 17, 2025 /PRNewswire/ -- the official website of the Yiwu Commodity Market, is the largest commodity wholesale market in the world. Big data from Yiwugo shows that, as of August 12, 2025, demand in the 'office and study supplies' sector had been on a steady rise, climbing to 14th place among all categories. Traditionally a stable segment of the consumer goods market, stationery has seen a notable surge in the past 30 days, driven by the approaching back-to-school season in both China and overseas. Many Yiwugo merchants report a buying wave for office essentials and cartoon-themed stationery. Jiangsu Dehuang Stationery Co., Ltd., with nearly 30 years of experience, boasts industry-leading design, R&D, and manufacturing capabilities. Over the years, it has established itself as a trusted supplier to both domestic and international brands. According to owner Wang Xiaohua, the company collaborates with renowned names such as Germany's Staedtler, Faber-Castell, and Pelikan, along with France's Maped and several leading Chinese brands. Its product line includes correction tools, sticky notes, and art crayons. Since early summer, demand from European customers for art-related products has soared, with average monthly purchases nearing RMB 1 million. The French market, in particular, has experienced a notable upswing, fueled by a wave of new customers introduced through Yiwugo. Major general merchandise chains in Japan, Europe, and the U.S. have expressed strong satisfaction with Dehuang's sticky notes, citing their exceptional paper durability, absence of fluorescent agent reactions, and outstanding adhesive stability—qualities that have translated into substantial annual orders. Wang noted that Dehuang's commitment to quality begins with the careful selection of premium raw materials and extends to the acquisition of both domestic and international certifications. Each year, the company undergoes rigorous brand-partner audits on plant design, technology, and supply capabilities. For instance, the production of correction fluid requires not only eco-friendly materials but also exceptional sealing performance. Factoring in production and transportation cycles, manufacturing a single bottle of Dehuang correction fluid costs about 1.5 times more than typical market alternatives—yet its shelf life is five to six times longer. This is a key reason for the company's consistently high customer retention rate. Unlike Dehuang, which has spent three decades building its reputation on quality, Yuanchang Stationery has distinguished itself through its distinctive design. According to proprietor Wu Chenjie, many customers have been sourcing office supplies via Yiwugo recently, with cartoon-themed staplers emerging as bestsellers. Models shaped like pandas, airplanes, and propellers have seen particularly strong demand. One European client, who initially ordered only a few hundred units of each model, quickly multiplied their orders severalfold after successful trial runs—yet demand still outpaced supply. Today, whenever Yuanchang introduces a new product, this client immediately places large orders; just this month, they purchased another shipment of cartoon staplers. As Wu pointed out, since 2023 Yuanchang has partnered with multiple design agencies to blend charm with functionality. The first major success from these collaborations—the panda stapler series—has become an overseas bestseller, now shipping more than 50,000 units each month. In recent months, Disney-themed stationery sets have been especially popular in Southeast Asia. After securing Disney licensing, Yuanchang has curated stationery collections tailored to different markets, with monthly orders reaching around 500,000 units. Currently, Yuanchang is busy fulfilling orders from a German retail chain. Through Yiwugo, the company has connected with a growing network of high-quality customers. Wu explained that their R&D team draws on both domestic and international feedback collected via the platform to refine their products, enhancing not only quality but also their playful appeal. Thanks to Yiwugo's outreach and promotion, an increasing number of premium Chinese brands—such as Dehuang—are gaining wider recognition in global markets, enabling outstanding domestic products to shine both at home and abroad. View original content to download multimedia: SOURCE
